Article

Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinoma

2021-04-04

Abstract excerpt

Activating mutations in the driver oncogene KRAS occur in 32% of lung adenocarcinomas, leading to more aggressive disease and resistance to therapy in preclinical studies. However, the association between KRAS mutational status and patient outcome or response to treatment remains unclear, likely due to additional events modulating RAS pathways. To obtain a broader measure of RAS pathway activation beyond KRAS m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a5468825-9125-5875-8f95-d0b66b1fb9c3
DOI: 10.1101/2021.04.02.437896

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Oncogenic RAS activity predicts response to chemotherapy and outcome in lung adenocarcinomaDOI 10.1101/2021.04.02.437896Read

RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.Semantic proximity Read

Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.Semantic proximity Read

Distinct molecular subtypes of KRASG12C-mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies.Semantic proximity Read

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.Semantic proximity Read

Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinomaSemantic proximity Read

Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read

KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.Semantic proximity Read

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.Semantic proximity Read

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.Semantic proximity Read

Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas.Semantic proximity Read

A Critical Review of the Prognostic and Predictive Implications of KRAS and STK11 Mutations and Co-Mutations in Metastatic Non-Small Lung CancerSemantic proximity Read

Mapping the mutational terrain of lung adenocarcinoma: A Danish cohort study of 880 patients.Semantic proximity Read